CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-03-04): FDA removes liver warning from Gilead drug

Regulatory

FDA removes liver warning from Gilead drug

Last Updated: 2011-03-04 13:37:21 -0400 (Reuters Health)

CHICAGO (Reuters) - U.S. health regulators removed warnings about potential liver damage from Gilead Sciences Inc's ambrisentan.

The drug, sold under the brand name Letairis, is a treatment to improve exercise ability and delay clinical worsening in patients with pulmonary arterial hypertension (PAH) and predominantly WHO Functional Class II-III symptoms.

Gilead said PAH patients receiving Letairis are no longer required to get monthly liver function tests.

On its website the company says the FDA decision was "based on its review of post-marketing data reflecting use of Letairis over more than 7,800 patient years.... During 12-week controlled clinical trials, the incidence of liver function abnormalities was 0% on Letairis and 2.3% on placebo."

Because of the risk of birth defects, Letairis continues to have a Boxed Warning.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.